AstraZeneca Pharma India informs about disclosure

26 Nov 2022 Evaluate

AstraZeneca Pharma India has informed that, AstraZeneca Pharma India has received an Import and Market permission in Form CT-20 (Subsequent New Drug Approval) from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for Dapagliflozin (Forxiga®) tablets of 10 mg - additional indication. Through this approval, the Company is permitted to deal in Dapagliflozin (Forxiga®) tablets of 10 mg in additional/expanded indication ‘to reduce the risk of sustained eGFR and kidney disease, cardiovascular death and hospitalization for heart failure in adult with chronic kidney disease at risk of progression’ with condition that:- it is indicated in adults for the treatment of patients of chronic kidney disease (CKD) up to eGFR of greater than or equal to 25ml/min/1.73m2. Below this, initiation of the treatment is not recommended however the patients may continue 10mg orally once daily to reduce the risk of eGFR decline, ESKD, CV death and hHF. The receipt of this permission paves way for the launch of Dapagliflozin (Forxiga®) tablets of 10 mg in India for the specified additional/expanded indication, subject to the receipt of related statutory approvals.

The above information is a part of company’s filings submitted to BSE.

Astrazeneca Pharma I Share Price

8665.50 -130.40 (-1.48%)
30-Apr-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1830.20
Dr. Reddys Lab 1183.00
Cipla 1549.65
Lupin 2094.65
Zydus Lifesciences 887.70
View more..
© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.
×
Please wait your portfolio is updating...